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Bone marrow stromal cells [BMSCs; also known as mesenchymal
stem cells (MSCs)] effectively suppress inflammatory responses in
acute graft-versus-host disease in humans and in a number of
disease models in mice. Many of the studies concluded that BMSC-
driven immunomodulation is mediated by the suppression of pro-
inflammatory Th1 responses while rebalancing the Th1/Th2 ratio
toward Th2. In this study, using a ragweed induced mouse asthma
model, we studied if BMSCs could be beneficial in an allergic, Th2-
dominant environment. When BMSCs were injected i.v. at the time
of the antigen challenge, they protected the animals from the
majority of asthma-specific pathological changes, including inhib-
ition of eosinophil infiltration and excess mucus production in the
lung, decreased levels of Th2 cytokines (IL-4, IL-5, and IL-13) in
bronchial lavage, and lowered serum levels of Th2 immunoglobu-
lins (IgG1 and IgE). To explore the mechanism of the effect we
used BMSCs isolated from a variety of knockout mice, performed
in vivo blocking of cytokines and studied the effect of asthmatic
serum and bronchoalveolar lavage from ragweed challenged
animals on the BMSCs in vitro. Our results suggest that IL-4 and/
or IL-13 activate the STAT6 pathway in the BMSCs resulting in an
increase of their TGF-β production, which seems to mediate the
beneficial effect, either alone, or together with regulatory T cells,
some of which might be recruited by the BMSCs. These data sug-
gest that, in addition to focusing on graft-versus-host disease and
autoimmune diseases, allergic conditions—specifically therapy
resistant asthma—might also be a likely target of the recently
discovered cellular therapy approach using BMSCs.
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Asthma is a chronic inflammatory airway disease affecting 16million people in the United States alone and more than 300
million worldwide (1). It can range from a mild, intermittent
disease to one that is severe, persistent, and difficult to treat (i.e.,
therapy-resistant) (2). Asthma-related deaths are uncommon,
but they appear to be increasing; currently there are approx-
imately 5,000 deaths per year in the United States and 100,000
throughout the world (3). New treatments are needed for ther-
apy-resistant, severe cases.
Bone marrow stromal cells (BMSCs) have recently been shown
to suppress harmful immune responses in patients with acute graft-
versus-host disease (4, 5) and in several animalmodels of allogeneic
rejection (6–8), a variety of autoimmune diseases (9–11), and lung
injury (12–15). The authors of many of these studies concluded that
BMSC-driven immunosuppression results from a shift in Th1/Th2
balance (8, 16, 17).DuringBMSC treatment, Th1 responses appear
to be decreasing while Th2 responses begin to dominate. In animals
with established allergies, Th2 responses are already dominant, and
we wondered how BMSCs would react to such an environment. In
this study we thus examined the effect of BMSCs on Th2-driven
allergic reactions in a mouse model of asthma (18, 19).
Results
Lung Pathology. Following ragweed (RW) challenge (for timing of
the events see Fig. 1), microscopic examination of the lungs showed
minimal or no inflammation in mice sensitized with PBS solution
and alum but no RW (Fig. 2A). Conversely, RW-sensitized mice
showed extensive inflammation with eosinophil and lymphocyte
invasion and severeperivascular andperibronchial cuffing (Fig. 2B).
Mice thatwere challengedwithRWbut treatedwith i.v. injectionsof
BMSCs had significantly less lung pathology: few inflammatory cell
infiltrates were observed (Fig. 2C). Although no abnormal mucus-
filled cells were observed in controls as defined by histological
staining using PAS (Fig. 2D), the amount of stainable mucus in the
airways was visibly increased following RW challenge (Fig. 2E).
BMSC treatment reduced the amount of mucus to near control
levels (Fig. 2F). In addition to improved lung scores (Fig. 3A), we
also observed a significant decrease in both total inflammatory cell
numbers and eosinophils in the bronchoalveolar lavage (BAL) fluid
(Fig. 3 B and C).
Cytokine Response. RW-challenged mice showed increased levels of
IL-4, IL-13, and IL-5 in BAL, all characteristic Th2 cytokines that
highlight allergic inflammation. IL-4 and IL-13 levels were sig-
nificantly reduced when the animals were treated with i.v. BMSCs
(Fig. 3 D–F).
Ig Response. RW sensitization and subsequent antigen challenge is
known to affect Th2-specific Ig concentrations in blood (19).
Indeed, we found that both IgG1 and IgE serum levels were sig-
nificantly increased following RW application, whereas IgG2a did
not change. BMSC treatment resulted in a significant decrease of
RWinducedelevation of IgG1and IgE concentrations (Fig. 3G–I).
Use of Allogeneic BMSCs or Skin Fibroblasts Instead of Syngeneic
BMSCs. In a few groups ofmice, we determinedwhether therewas a
difference in effect when we use allogeneic BMSCs prepared from
Balb/C mice or syngeneic C57BL/6J dermal fibroblasts instead of
syngeneic (C57/BL6) BMSCs. We measured total cell numbers
and the number of eosinophils (Fig. 4 A and B) as well as IL-4 and
IL-13 levels (Fig. 4C andD) fromBALand immunoglobulins from
serum (Fig. 4 E–G). We found that there was no significant dif-
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ference between syngeneic versus allogeneic BMSCs (i.e., both
were equally effective), and skin fibroblasts had only partial effect.
Although the number of total cells in BAL was reduced following
fibroblast treatment, the number of eosinophils was not different
from the untreated group. Fibroblasts behaved similarly toBMSCs
in regulating cytokine levels, but they had no effect on serum IgE
concentrations. Interestingly, IgG2a levels were highly increased
following fibroblast administration—an effect that we never
observed using BMSCs.
Searching for Mechanism of Action. One hour after i.v. injection of
BMSCs on d 14, the cells were found exclusively in the lung
whereas virtually no cells were seen in other organs as demon-
strated by bioluminescence measurements using luciferase
expressing stromal cells (Fig. 5A). To determine if the inflam-
matory environment seen in asthma could influence homing to
and/or survival of BMSCs in the lung, we injected luciferase-
expressing cells into animals on d 14, immediately after intra-
airway application of PBS solution or RW. Comparing emitted
luminescence at different time points we assessed the number of
stromal cells still present in the lungs. At 1, 12, and 24 h, the
number of BMSCs in control and asthmatic animals were com-
parable, whereas at 36 h—and more evidently after 48 h—we
detected considerably more BMSCs in the asthmatic lungs (Fig.
5A). To follow up on this observation, we injected Q-dot–labeled
BMSCs into control and RW-challenged animals and isolated
the Q-dot–positive BMSCs from the protease-digested lung cell
suspensions using FACS. At 6, 12, and 24 h after injection, the
number of Q-dot–positive cells did not differ between the two
groups. After 36 h, however, we detected a significant increase in
the number of BMSCs retained in the asthmatic lungs, and this
difference remained detectable at 48, 72, and 96 h after BMSC
injection (Fig. 5 B and C). These observations suggest that the
developing allergic environment is capable to attract and retain
more BMSCs than unaffected lungs, indicating that asthmatic
lungs are likely to secrete factors that affect BMSC homing and
survival. We next continued to explore the nature of such factors.
Among the number of cytokines known to suppress allergic
responses the antiinflammatory actions of IL-10, TGFβ, and IFN-γ
are especially well established. To determine whether any of these
factors contributes to the beneficial effect of BMSCs, we first
examined their levels inBALfluid. Therewas a significant increase
in the level of TGF-β in BAL fluid collected from BMSC-treated
versus untreated mice, but no change in IFN-γ or IL-10 levels
(Fig. 6 A–C). As TGF-β was increased in BAL fluid, and BMSCs
are reported to be able to secrete TGF-β (20), we next asked
whether serum or BAL fluid from RW-challenged mice could
affect TGF-β production by BMSCs in vitro. TGF-β increased
in themediumwhenBMSCswere cultured in the presence ofRW-
challenged serum or BAL, suggesting that allergy-specific micro-
environment (i.e., serum or BAL) is capable of modulating
immunoregulatory functions of BMSCs. It has been reported that
stimulation of certain immune cells through the IL-4R pathway
results in up-regulated TGF-β expression (32). To find out if
enhanced TGF-β production by BMSCs in the presence of allergic
Fig. 1. Timeline of the experiments showing the days of the interventions.
Fig. 2. Histological images of airways stained with PAS to show the mucin-
producing goblet cells (dark red in the lumen). Low-magnification images
depict a control lung (A), a lung following RWchallengewith no treatment (B),
and a lung with BMSC treatment (C). Note the significant increase in lym-
phocytic infiltrates (arrows) in B and their decrease in C. The high magnifica-
tion images of the airways show a normal bronchus inD, a bronchus from RW-
challengedmousewithmucusbuildup (arrows) in the luminal surface (E), anda
treatedmousewith lessmucus in F. (Scale bar, 250 μm inA–C and50 μm inD–F.)
Fig. 3. Evaluation of the effect of BMSC treatment on the different
parameters of RW-induced asthma. Mice treated with BMSCs showed a
significant reduction in lung histology scores (A), total number of BAL cells
(B), relative ratio of BAL eosinophils (C), and levels of allergy-specific Th2
cytokines IL-4 (D), IL-13 (E), and IL5 (F) in BAL. From the sera of challenged
mice we measured Ig concentrations, and in the BMSC-treated group we
found a significant decrease in the level of Th2-specific Ig concentrations
IgG1 (G) and IgE (H), whereas there was no change in the level of IgG2a (I).
There were four to eight mice per group. *P < 0.05, **P < 0.01, and ***P <
0.001 in all graphs.







serum or BAL could be triggered by activation through the IL-4R,
we repeated the aforementioned experiments using IL-4R–
deficient BMSCs. We found that RW-challenged serum or BAL
could not enhance TGF-β production in IL-4R–KO BMSCs,
suggesting an important role for IL-4 (Fig. 6D).
As both IL-4 and IL-13 are able to bind to IL-4R, in another
series of experiments we examined the effect of blocking (using
specific antibodies) IL-4, IL-13, or both on the TGF-β production
byBMSCswhen they came in contactwithRW-sensitized serumor
BAL (Fig. 6E and F).When serum fromRW challengedmice was
added to the media, IL4 neutralization alone eliminated the
increased TGF-β production but blocking IL-13 did not have this
effect (Fig. 6E). Interestingly, when BAL from RW challenged
mice was added, the BMSCs increased their TGF-β production
even when either IL-4 or IL-13 was blocked; however, blocking
both cytokines simultaneously eliminated the effect (Fig. 6F). On
the other hand, neither recombinant IL-4 or IL-13 alone or in
combination increased TGF-β production (Fig. S1), suggesting a
possible role for other factors.
When treating mice with TGF-β– and IL-10–specific neutral-
izing antibodies beforeBMSC injection, we observed that blocking
TGF-β—but not IL-10—eliminated the beneficial effect of
BMSCs demonstrated by the lack of reduction in BAL total cell
numbers and eosinophil counts (Fig. 7 A and B). Furthermore, in
mice injected with TGF-β1–KO BMSCs, the beneficial effect was
no longer seen: treated animals showed no reduction in BAL cell
numbers, asthma-specific BAL cytokines, or serum Th2 immu-
noglobulins. Importantly TGF-β1–KO cells were unable to elicit
increase in BAL TGF-β concentrations, suggesting that BMSC-
derived TGF-β1 is responsible for the effect (Fig. 7C).
The IL-4 receptor is known to activate the STAT6 signaling
pathway (21). To see if the IL4Ra/STAT6 pathway is indeed
necessary for the BMSCs to act beneficially in an allergic envi-
ronment—as suggested by the in vitro studies just described—we
injected STAT6-deficient BMSCs instead of WT cells and
observed no TGF-β elevation in the BAL samples (Fig. 7C). In













































































































Fig. 4. Assessing the effect of allogeneic BMSCs or syngeneic skin fibroblasts on RW-induced asthma. Allogeneic BMSCs exhibit a similar inhibitory effect as
syngeneic BMSCs on the total number of BAL cells (A), relative ratio of eosinophils (B), BAL inflammatory cytokines IL-4 (C) and IL-13 (D), and serum
immunoglobulins IgG1 (E), IgE (F), and IgG2a (G). There were four to eight mice per group. Skin fibroblasts had a partial effect on the aforementioned
parameters (see same graphs).
Fig. 5. After i.v. delivery of BMSCs at the time of the first challenge, stromal cells are concentrated in the lung. Asthmatic lungs seem to retain more BMSCs
than control unchallenged lungs at 48 h after administration, demonstrated by bioluminescence detection of luciferase-expressing stromal cells. Two rep-
resentative mice of three used are shown (A). To confirm this observation, Q-dot–labeled BMSCs were injected at the time of the first challenge, and lung cell
suspensions were analyzed using FACS at several time points after injection. After 6 h, the number of Q-dot–positive cells (BMSCs) are still comparable in the
two groups (each had four mice), but starting at 12 h there are significantly more BMSCs retained in the asthmatic lungs compared with the controls at all
time points examined (B and C).
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the BMSC-derived attenuation of RW-induced asthma, pointing
to the importance of the IL4R/STAT6 pathway (Fig. 7 D–J).
As regulatory T cells (T-regs) are known to play a role in
alleviating asthma symptoms and TGF-β has been suggested to
play a role in T-reg differentiation, we wondered if the number
of T-regs in the lung tissue could also be affected by the BMSC
treatment in our model. Analyzing lung single cell suspensions
using FACS, we detected a steady increase in the number of
T-regs in challenged animals over time. Importantly, as early as
after 48 h, as well as after 72 and 96 h after challenge, we found
significantly more T-regs in the BMSC-treated lungs than the
ones collected from challenged but untreated animals (Fig. 8).
Discussion
Asthma is an inflammatory disease of the airways. In asthma, the
lungs are invaded by a variety of inflammatory cells, including
eosinophils and lymphocytes. These cells, in addition to resident
mast cells, secrete cytokines and chemokines that trigger con-
striction of the bronchi and secretion of mucus.
The current working hypothesis is that asthma is caused by an
abnormal shift in the Th1/Th2 balance in favor of Th2 cells and
the production of IL-4, IL-5, and IL-13. Through these mediators,
Th2 lymphocytes are thought to recruit additional effector cells to
the lungs, and the cells recruited promote allergic inflammatory
events (22). BMSCs have been shown to have useful effects in a
number of diseases and disease models. In the majority of these
disorders, however, the T cell balance is shifted toward Th1
dominance. As BMSCs seem to “normalize” immune responses
and reestablish the physiological balance in a variety of auto-
immune and infectious diseases (23–27), we wondered whether
these cells might also be able to tip the balance back to normal in
an allergic environment with already-established Th2 dominance.
The rebalancing act would require that the cells detect an
imbalance and then take appropriate measures to correct it.
Our initial experiments showed that injecting BMSCs on d 14,
when first challenging the sensitized animals significantly
improved lung pathology, such as total cell number in BAL;
number of eosinophils in BAL and lung scores. Using luciferase-
expressing or Q-dot–labeled BMSCs, we demonstrated that
lungs are the primary site of BMSC accumulation following i.v.
injection, confirming the known phenomenon of cell trapping in
the pulmonary microvasculature that is partially related to cell
size (28, 29). However, using Q-dot–labeled BMSCs we found
significantly more BMSCs retained in the lungs when RW-
induced allergic inflammation was present compared with the
unchallenged state—a tendency also suggested by the bio-
luminescent measurements. As in our model, the primary site of
pathologic processes is the lung itself, and the enhanced pres-






Fig. 6. Studying the mechanism of BMSC effect. In BAL BMSC treatment
resulted in elevated TGF-β levels (A). IFN-γ (B) and IL-10 (C) did not change.
Serum or BAL from RW challenged mice induced BMSCs to producemore
TGF-β in vitro, but this effect was eliminated when BMSCs lacked IL-4Ra (D).
Using neutralizing antibodies for IL-4 or IL-13 suggested both cytokines are
involved in stimulating BMSC’s TGF-β production when cocultured with
serum (E) or BAL (F) from RW challenged mice.
Fig. 7. In vivo demonstration of mechanism of action. The beneficial effect of
BMSCs on inflammatory changes is eliminated in the presence of TGF-β neu-
tralizing antibodies, but spared when animals are treated with anti-IL-10 anti-
bodies (A and B). BMSCs from TGF-β or STAT6 deficient animals did not induce
TGF-βproduction (C ) ordecreaseBALtotal cellnumbers (D), eosinophil numbers
(E), cytokine levels (F and G), or serum immunoglobulin concentrations (H–J).
Fig. 8. Quantification of regulatory T cells in asthmatic lungs. With time
there is a gradual increase in the number of regulatory T cells in lungs
challenged with RW. BMSC-treated asthmatic lungs show a greater influx of
T-regs starting at 36 h after challenge and further increasing up to 96 h.







IL-10 and TGF-β, two well characterized antiinflammatory
cytokines, and IFN-γ, a key Th1 cytokine capable of down-
regulating Th2-mediated pathological responses, are all thought
to be capable of suppressing asthma (22, 30). As IL-10 has been
shown to play a significant role in the beneficial effect of BMSCs in
sepsis (27), we first measured cytokines in serum and BAL in the
treated versus untreated RW-challenged mice. We found no
change in IL-10 or IFN-γ levels, but therewas a significant increase
in the level of TGF-β, suggesting a different mechanism of action
than what was found in a septic environment. We then demon-
strated the importance of TGF-β in vivo by treating the mice with
TGF-β–specific neutralizing antibodies before BMSC injection.
Blocking TGF-β—but not IL-10—eliminated the beneficial effect
of BMSC treatment. Next we looked for a possible source of
TGF-β. BMSCs themselves are capable of secreting TGF-β (31),
which has been implicated as one of the possible mediators of the
BMSCs’ immunosuppressive effect. We thus repeated the
experiment injecting BMSCs derived from TGF-β1–KOmice and
found no beneficial effect, suggesting that the BMSC-derived
TGF-β is critical in suppressing the allergic responses. As TGF-β
synthesis can be enhanced through IL-4R in some immune cells
(32), we wondered if it is the IL-4 and IL-13 that “turns on” the
BMSCs to make TGF-β. We first used BMSCs from mice lacking
the IL-4R (which is used by both IL-4 and IL-13) and found that
RW-challenged serum or BAL could no longer elicit increased
TGF-β production in these cells in vitro. In another set of
experiments using neutralizing antibodies against IL-4 or IL-13,
we could further demonstrate the importance of the IL4R. As the
IL-4R is known to activate the STAT6 pathway (21), we wanted to
confirm our results by using BMSCs that genetically lacked
STAT6. As expected, STAT6-KO BMSCs were ineffective in
alleviating asthma pathology and could not trigger TGF-β ele-
vation in the BAL fluids either. Based on these data, we suggest
that IL-4 and/or IL-13 bind to IL-4R receptors on BMSCs acti-
vating the STAT6 pathway. This, in turn, drives the cells to pro-
duce increased amounts of TGF-β. When this TGF-β is released
from the BMSCs in the allergic (i.e., Th2-dominant) environment,
TGF-β receptor activation on immune cells could result in a
decrease in IL-4 production (33) and ultimately leads to a shift
back toward immunological equilibrium (Fig. 9). Surprisingly,
neither recombinant IL-4 nor IL-13 alone or in combination was
able to elicit the elevation of TGF-β by BMSCs seen with RW-
conditioned BAL fluid or blood serum in vitro. This indicates that
activation of the IL-4R/STAT6 pathway is necessary but not suf-
ficient to cause TGF-β up-regulation in BMSCs. In addition to IL-
4 or IL-13, theremust be other important factors in vivo (present in
BAL fluid or serum) that contribute to the production and sub-
sequent release of TGF-β by BMSCs.
We also demonstrated that BMSC-treated asthmatic animals
recruit significantly more regulatory T cells to the lungs than
untreated mice. In animal models of allergic airways disease,
T-regs can suppress established airway inflammation and airway
hyperresponsiveness (34). Regulatory T cells are thought to sup-
press infection/inflammation by secreting antiinflammatory mol-
ecules (e.g., IL-10, TGF-β) (35, 36). It is possible that BMSCswork
together with regulatory T cells to suppress harmful allergic
responses in our model. BMSCs could initiate the suppressive
process by secreting TGF-β to block the proinflammatory Th2
responses and at the same time induce the differentiation and help
the survival of regulatory T cells (30) that will then continue to
improve asthma pathology after the BMSCs disappear.
It is worth mentioning that dermal fibroblasts—cells frequently
used as control cells in studies of BMSCs—had beneficial effects in
the model that we used when injected intravenously. The effect of
the fibroblasts was not as strong as that of BMSCs. This suggests,
however, that fibroblast-like cells, whether derived from the bone
marrow or other organs (including skin dermis), may also have
some immunomodulatory properties (37).
In the present study we demonstrated that i.v. injected BMSCs
are capable of suppressingTh2-driven allergic responses. It appears
that IL-4 and/or IL-13 induce production and secretionofTGF-β by
the BMSCs, which in turn effectively suppresses allergy specific
pathological changes in the asthma model we studied. These data
provide another example of the ability of BMSCs to “sense” their
immunological environment and respond accordingly. It is hard to
imagine a drug or combination of drugs that could act this way, and
furtherwork shouldbedone to determinewhether the cells couldbe
used to treat patients with therapy-resistant asthma.
Methods
Mice. C57BL/6J or Balb/C mice (6 to 8 weeks old) were obtained from Taconic
Farms. IL-4Rα–KO and STAT6-KO animals were purchased from Jackson
Laboratories. TGF-β1–KO mice have previously been produced and charac-
terized (38). The animals were housed and maintained in the National
Institute of Allergy and Infectious Diseases or National Institute of Dental
and Craniofacial Research animal facilities. All studies conformed to the
principles for laboratory animal research outlined by the Animal Welfare
Act, and were approved by the National Institute of Dental and Craniofacial
Research and/or National Institute of Allergy and Infectious Diseases Animal
Care and Use Committee. The groups for in vivo studies contained four to 10
mice, and each experiment was repeated two to three times.
Antigen Challenge. To elicit a bronchial allergic response, RW sensitization and
challenge were used (18, 19). C57BL/6J mice were sensitized on d 0 and 5
with 200 μL i.p. injections of 50 μg RW extract (Greer Laboratories), emul-
sified in an equal volume (100 μL/antigen injection) of alum (Pierce) as
described earlier (39). Control animals were injected i.p. with the same
amount of alum mixed with PBS solution. Subsequently, as shown in Fig. 1,
the mice were challenged on d 14 and 15 with 50 μg RW extract in PBS
solution by intratracheal and intranasal inoculation (30 μL), respectively.
Control mice received an equal volume of PBS solution administered via the
same routes. In all cases, mice were killed by anesthetizing them with ket-
amine (Fort Dodge Animal Health) and xylazine (Phoenix Pharmaceuticals)
100 mg/kg and 10 mg/kg, respectively, followed by exsanguination.
Histology. Toassesspulmonaryinflammation,BALwasperformed72hafterthe
final allergen challenge (as described later). Lungs were then immediately
placed in 10% neutral buffered formalin and sent to Histoserv (Germantown,
MD), where they were embedded in paraffin and stained. H&E was used to
evaluate cellular inflammationandperiodic acid–Schiff (PAS) stainwasused to
visualizemucus-containing goblet cells. Slides were coded and read “blind”; a
minimumof four lungs per groupwere given scores ranging from 0 to 2 based
on the level of peribronchial cuffing, perivascular cuffing, goblet cell hyper-
plasia, and interstitial inflammation (40).
Fig. 9. Schematic drawing shows the mechanism of effect based on data of
the present study. BMSCs “sense” the allergic environment, and as a result of
the increased levels of IL-4/IL-13, they respond by producing higher amounts
of TGF-β that, either alone or by recruiting regulatory T cells, will ultimately
lead to a decrease of lung eosinophil infiltration, as well as allergy-specific
cytokine and Ig production.
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BAL. Immediately after the mice were exsanguinated, the lungs were can-
nulated with a 20-gauge i.v. catheter and gently washed once with 500 μL 1%
FBS (HyClone) in PBS solution (for cytokine analysis) or twice with 750 μL 1%
FBS in PBS solution (for analysis of cellular infiltration). Samples for cytokine
analysis were stored at −80°C. Samples for cellular analysis were spun onto
glass slides in a cytospin instrument (Thermo-Shandon) and stained with
Kwik-Diff for differential cell analysis (Thermo-Shandon). A fraction was
used to determine total cell counts.
In Vivo Neutralization of Cytokines. IL-10– or TGF-β–neutralizing antibodies
(Clone 2A5 from Pierce Endogen or Clone 1D11 from R&D Systems, respec-
tively) were injected intraperitoneally (10 μg/g body weight in 200 μL PBS) on
two consecutive days at the approximate time of BMSC injection (d 14
and 15).
Measurement of Serum Antibody Isotypes. Antibody isotypes (IgG1, IgG2a, and
IgE) were assayed in sera collected 72 h after last RW challenge using ELISA kits
according to the manufacturer’s instructions (Immunology Consultants Labo-
ratory). All samples, including standards, were assayed in duplicate.
Preparation of Lung Cell Suspension. Lungs were removed, minced into small
pieces, and incubated in RPMI medium 1640 with 1% penicillin–streptomycin
and 1% glutamine for 30 min at 37 °C 5% CO2 in the presence of collagenase
type 1 (300 U mL−1) and DNase I (50 U mL−1; Worthington Biochemicals).
After the incubation, the cell suspension was filtered through a 70-μm cell
strainer and then washed with complete RPMI medium.
Data Analysis. Data are summarized as mean ± SE. Student t test or two-way
ANOVA were performed using GraphPad Prism version 4.00 for Macintosh
(GraphPad Software). The statistical significance value was set at P < 0.05.
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